The Week

Strive rallied 19.32% this week to close at $21.74, against a 0.49% rise in the S&P 500, outperforming the benchmark by 18.83 percentage points. The move was a spike-and-fade: the stock opened at $18.76 on Monday, climbed into Thursday when it touched a weekly high of $24.38, then pulled back on Friday to close at $21.74. Weekly amplitude reached 31.08%, with daily turnover averaging 12.51m shares, well above the prior median.\n\n## Key Events\n\nBitcoin accumulation dominated the story. On Tuesday the company disclosed an $81.5m purchase of 1,110 Bitcoin, taking its total holdings to 21,000 BTC; shares rose roughly 11% that day. Over the following sessions, options desk coverage flagged sharp gains in call contracts, up 223%, 134% and 162% from Monday to Thursday. By Saturday, reports noted Strive added 2,680 Bitcoin in five days, marking what the news called its best week ever.\n\n## Analyst Ratings\n\nFive brokers cover the stock, with four issuing buy ratings and one at overweight; none rate it hold, underweight or sell. Consensus is strong buy, with a target of $26.6, about 22.36% above the latest close of $21.74. The target range runs from $16 to $36, indicating wide dispersion. Among 141 medical device names, Strive’s rating rank sits 56th.\n\n## The Week Ahead\n\nSeveral US macro releases follow next week: Dallas Fed manufacturing activity on Monday, S&P Global and ISM manufacturing PMIs plus JOLTS job openings on Tuesday, and ADP private payrolls, factory orders and EIA crude stockpiles on Wednesday. For a high-volatility name like Strive, shifts in macro liquidity expectations can weigh on risk appetite, so the post-data market tone will matter.\n\n## In Short\n\nStrive’s rally coincided with large Bitcoin purchases and a stretch of surging call options, signalling elevated trading heat. Yet the company posts negative earnings and a PB near 2.33, with no margin of safety on valuation. The latest session showed large-lot money turning net seller while small-lot orders were net buyers, a split in direction. Brokers remain consistently buy-rated and their consensus target sits more than 20% above spot. The question now is whether accumulation continues and whether that institutional optimism holds up in a choppy tape.\n\nThis article is generated by LongbridgeAI from market data, for information only and not investment advice.